Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior's New Suboxone Patent Cannot Keep Dr. Reddy's Generic Off Market

Executive Summary

US Federal Circuit applies new standard in finding continuation patent claims are indistinct from those in parent patent, vacates preliminary injunction.
Advertisement

Related Content

US Suboxone Win Lifts Dr Reddy’s As Embattled Indivior Fights On
Teva Sues US FDA To Obtain 180-Day Exclusivity For Its Generic Restasis
Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel